It targets AMPKα2 for ubiquitination and degradation in skeletal muscle, inhibiting the AMPK signaling pathway and thereby leading to insulin resistance and metabolic disorders (Table 3). The gene discussed is PRKAA2; the disease is Other metabolic disease.